Drug intelligence / Profile preview

nalbuphine + bupivacaine

Development stage
Phase 4
Lead developer
Cairo University
Modality
Small Molecules
Administration
Perineural
01

Overview

This is a combination of nalbuphine, a mixed opioid agonist-antagonist, and bupivacaine, a long-acting local anesthetic. It is being investigated by Cairo University as a perineural adjuvant in ultrasound-guided superficial cervical plexus blocks to manage postoperative pain in patients undergoing thyroidectomy. Nalbuphine acts as an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors, which provides analgesia while potentially limiting mu-mediated side effects. Bupivacaine blocks voltage-gated sodium channels to inhibit nerve conduction. The study aims to determine if adding nalbuphine to bupivacaine prolongs the duration of analgesia and reduces the requirement for rescue analgesics following surgery.

Other names
nalbuphine as an adjuvant to bupivacaine
02

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on nalbuphine + bupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nalbuphine + bupivacaine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call